ArrowMark Colorado Holdings’s Celldex Therapeutics CLDX Stock Holding History

ArrowMark Colorado Holdings’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-25,000	Closed	-$793K	–	299
2026 Q1	$793K	Hold	25,000	–	–	0.02%	251
2025 Q4	$679K	Hold	25,000	–	–	0.01%	274
2025 Q3	$647K	Hold	25,000	–	–	0.01%	267
2025 Q2	$509K	Hold	25,000	–	–	0.01%	273
2025 Q1	$454K	Hold	25,000	–	–	0.01%	274
2024 Q4	$632K	Hold	25,000	–	–	0.01%	274
2024 Q3	$850K	Hold	25,000	–	–	0.01%	255
2024 Q2	$925K	Hold	25,000	–	–	0.01%	267
2024 Q1	$1.05M	Buy	+25,000	New	+$1.03M	0.01%	265
2013 Q4	–	Sell	-3,635	Closed	-$1.93M	–	321
2013 Q3	$1.93M	Buy	3,635 +615	+20%	+$211K	0.06%	186
2013 Q2	$707K	Buy	+3,020	New	+$595K	0.19%	74

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ArrowMark Colorado Holdings's CLDX Position: Q2 2026 in Review

ArrowMark Colorado Holdings sold out of Celldex Therapeutics (CLDX) in Q2 2026, closing a stake of 25,000 shares — an estimated $793K sold.

ArrowMark Colorado Holdings first reported a position in CLDX in Q2 2013 and held it in 11 quarters. The position peaked at $1.93M in Q3 2013. 254 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

ArrowMark Colorado Holdings reported no remaining Celldex Therapeutics position as of Q2 2026 after selling out during the quarter.
ArrowMark Colorado Holdings sold 25,000 Celldex Therapeutics shares in Q2 2026, an estimated $793K.
ArrowMark Colorado Holdings first reported a position in Celldex Therapeutics in Q2 2013 and held it in 11 quarters.
ArrowMark Colorado Holdings's Celldex Therapeutics position peaked at $1.93M in Q3 2013.
254 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on ArrowMark Colorado Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.